Eli Lilly reports fiscal Q2 2026 results: revenue $22.97B, up 48% from a year earlier

Eli Lilly filed a Form 8-K with the SEC on Aug 5, 2026, 7:05 AM ET, reporting an event dated Aug 5, 2026. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q2 2026 (quarter ended Jun 30, 2026); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $22.97B (+47.7% from $15.56B a year earlier)
• Net income: $7.09B (+25.3% from $5.66B a year earlier)
• Diluted EPS: $7.94 (+26.2% from $6.29 a year earlier)
• Form 8-K accepted by EDGAR Aug 5, 2026, 7:05 AM ET
• Accession number 0000059478-26-000077

SEC filing 8-K · accession 0000059478-26-000077 · sec.gov ↗